𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson's disease

✍ Scribed by Lissa S. Brod; Jason L. Aldred; John G. Nutt

Book ID
112143396
Publisher
John Wiley and Sons
Year
2012
Tongue
English
Weight
731 KB
Volume
27
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Double-blind trial of levodopa/carbidopa
Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease
✍ Robert A. Hauser; Michel Panisset; Giovanni Abbruzzese; Linda Mancione; Nalina D πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 443 KB

## Abstract We performed a 39‐week, randomized, double‐blind, multicenter study to compare the efficacy, safety, and tolerability of levodopa/carbidopa/entacapone (LCE, Stalevo) with levodopa/carbidopa (LC, Sinemet IR) in patients with early Parkinson's disease (PD). Four hundred twenty‐three patie

Twice-daily, low-dose pramipexole in ear
Twice-daily, low-dose pramipexole in early Parkinson's disease: A randomized, placebo-controlled trial
✍ Karl Kieburtz; The Parkinson Study Group PramiBID Investigators πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 137 KB πŸ‘ 1 views

## Abstract To compare the safety and efficacy of low dosages of pramipexole given twice daily (bid) in early Parkinson's disease (PD) with those of a standard 3 times daily (tid) regimen in a randomized, double‐blind, placebo controlled trial involving 311 early PD patients not receiving dopaminer